1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 36,61€ (+188,95%). The median is 38,61€ (+204,74%).
| Buy |
3 |
| Hold |
3 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 3,50k | 48,36% |
| Gross profit | 3,50k | 48,36% |
| Net profit | −39,21M | 8,29% |
| EBITDA | −37,27M | 3,21% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 325,71M€ |
Number of shares | 24,50M |
52-week high/low | 38,61€ - 9,24€ |
| Dividends | No |
Beta | -0,07 |
P/E ratio | −0,97 |
PEG ratio | 0,01 |
P/B ratio | 1,55 |
P/S ratio | 14.058,24 |
Company profile
| Name | LYELL IMMUNOPHARMA |
| CEO | Lynn Seely |
| Headquarters | South San Francisco,
ca USA |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 161 |
Discover assets
Shareholders of LYELL IMMUNOPHARMA also invest in the following assets
